Percentage of patients who had reached Threshold Disease, for L≥40 vs L<40 groups, by each time point. At each time point, patients are further sub-classified as having reached threshold based on the indication for keratoplasty, fulfilment of the pachymetry criteria or fulfilment of the endothelial cell density criteria. *Statistically significant difference in Threshold Disease proportions between L≥40 and L<40 groups, at 5-years (p = 0.012). There were no statistically significant differences in Threshold Disease proportions between the 2 groups at the 1-year (p = 0.227), 3-year (p = 0.065), 8-year (p = 0.278) or 10-year (p = 0.426) time-points.</p
Background: The optimal volumetric threshold for determining progressive disease (PD) in recurrent g...
<p>Patients belonging to the low-MxA group (MxA <1.096) showed a significantly longer time to increa...
<p>* Presence of palpable nodules was not an inclusion criterion.</p><p>** Based on histological exa...
1. benefit 30%, harm = 5%, threshold = 17% (- - -), 2. benefit 40%, harm = 5%, threshold = 12.5% (--...
<p>GPC; general population comparators.</p><p>py; person-years. Person years defined as starting at ...
<p>Cartoon illustrating two distinct, unrelated, values that are both called “threshold”. The statis...
<p>Proportion of patients with (A) 6-month and (B) 12-month confirmed EDSS progression during months...
<p>(A)The disease progression-free rate for those with clinical stage IV was significantly lower tha...
BACKGROUND AND PURPOSE: The timed 25-foot walk (T25FW) and nine-hole peg test (NHPT) exhibit random ...
Top: Number of recurrent changepoints identified across all cancer types depending on which number o...
<p>Percentage of patients remaining after introduction of different selection criteria used in six l...
<p>Percentages of benign and malignant Type 1 (persistent enhancing), Type 2 (plateau) and Type 3 (w...
*<p>Total number of participants seen at 12 and 24 months. On occasion, a specific part of the exami...
<p><sup>a</sup> short-term survivors have an overall survival time < 24 months.</p><p><sup>b</sup> l...
<p>Protienuria threshold values by clinical test. Threshold values are adapted from the 2008 NICE gu...
Background: The optimal volumetric threshold for determining progressive disease (PD) in recurrent g...
<p>Patients belonging to the low-MxA group (MxA <1.096) showed a significantly longer time to increa...
<p>* Presence of palpable nodules was not an inclusion criterion.</p><p>** Based on histological exa...
1. benefit 30%, harm = 5%, threshold = 17% (- - -), 2. benefit 40%, harm = 5%, threshold = 12.5% (--...
<p>GPC; general population comparators.</p><p>py; person-years. Person years defined as starting at ...
<p>Cartoon illustrating two distinct, unrelated, values that are both called “threshold”. The statis...
<p>Proportion of patients with (A) 6-month and (B) 12-month confirmed EDSS progression during months...
<p>(A)The disease progression-free rate for those with clinical stage IV was significantly lower tha...
BACKGROUND AND PURPOSE: The timed 25-foot walk (T25FW) and nine-hole peg test (NHPT) exhibit random ...
Top: Number of recurrent changepoints identified across all cancer types depending on which number o...
<p>Percentage of patients remaining after introduction of different selection criteria used in six l...
<p>Percentages of benign and malignant Type 1 (persistent enhancing), Type 2 (plateau) and Type 3 (w...
*<p>Total number of participants seen at 12 and 24 months. On occasion, a specific part of the exami...
<p><sup>a</sup> short-term survivors have an overall survival time < 24 months.</p><p><sup>b</sup> l...
<p>Protienuria threshold values by clinical test. Threshold values are adapted from the 2008 NICE gu...
Background: The optimal volumetric threshold for determining progressive disease (PD) in recurrent g...
<p>Patients belonging to the low-MxA group (MxA <1.096) showed a significantly longer time to increa...
<p>* Presence of palpable nodules was not an inclusion criterion.</p><p>** Based on histological exa...